Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7367 in Advanced Solid Tumors
NCT05740202Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of SHR-7367 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicities at 3 weeks, Recommended phase II dose at 21 days and 1 more. Started Mar 2023; status: completed.
02
Drugs
SHR-7367
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05740202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740202.